The prognostic potential and carcinogenesis of long non-coding RNA TUG1 in human cholangiocarcinoma

Yi Xu1,2, Kaiming Leng1, Zhenglong Li1,2, Fumin Zhang1,2, Xiangyu Zhong1, Pengcheng Kang1, Xingming Jiang1 and Yunfu Cui1

1Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China
2Department of The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry of Education, Harbin, China

Correspondence to: Yunfu Cui, email: yfcui777@hotmail.com
Xingming Jiang, email: xmjiang@hrbmu.edu.cn

Keywords: cholangiocarcinoma, IncRNA, TUG1, prognosis, EMT

Received: February 02, 2017 Accepted: June 30, 2017 Published: July 22, 2017

Copyright: Xu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Cholangiocarcinoma (CCA) is a fatal disease with increasing worldwide incidence and is characterized by poor prognosis due to its poor response to conventional chemotherapy or radiotherapy. Long non-coding RNAs (IncRNAs) play key roles in multiple human cancers, including CCA. Cancer progression related IncRNA taurine-up-regulated gene 1 (TUG1) was reported to be involved in human carcinomas. However, the impact of TUG1 in CCA is unclear. The aim of this study was to explore the expression pattern of TUG1 and evaluate its clinical significance as well as prognostic potential in CCA. In addition, the functional roles of TUG1 including cell proliferation, apoptosis, migration, invasion and epithelial-mesenchymal transition (EMT), were evaluated after TUG1 silencing. Our data demonstrated up-regulation of TUG1 in both CCA tissues and cell lines. Moreover, overexpression of TUG1 is linked to tumor size (p=0.005), TNM stage (p=0.013), postoperative recurrence (p=0.036) and overall survival (p=0.010) of CCA patients. Furthermore, down-regulation of TUG1 following RNA silencing reduced cell growth and increased apoptosis in CCA cells. Additionally, TUG1 suppression inhibited metastasis potential in vitro by reversing EMT. Overall, our results suggest that TUG1 may be a rational CCA-related prognostic factor and therapeutic target.

INTRODUCTION

Cholangiocarcinoma (CCA) is a carcinoma derived from neoplastic transformation of biliary epithelial cells located in the intrahepatic and extrahepatic bile ducts. It is the second most common primary liver malignant tumor after hepatocellular carcinoma (HCC) and the most common biliary tract malignancy worldwide [1, 2]. Depending on its anatomic location, CCA is generally classified into three types, intrahepatic cholangiocarcinoma (ICC), hilar cholangiocarcinoma and extrahepatic cholangiocarcinoma (ECC) [3]. CCA is a deadly carcinoma with poor prognosis worldwide and is characterized by its resistance to conventional chemotherapy and radiotherapy, in addition to a lack of available methods for early diagnosis and treatment [4, 5]. Unfortunately, the majority of patients diagnosed with CCA present are at an advanced stage [6]. Surgical resection, along with liver transplantation, is still the most powerful therapy to cure CCA and leads to long-term survival. However, surgery is only possible in a significant minority of patients who present at an early stage and the 5-year survival rate of CCA is only 10% [7]. Recent molecular biology studies on the pathogenesis of CCA may provide valid treatment strategies and improve the prognosis of CCA [8]. However, the precise mechanism associated with malignant pathogenesis and progression of CCA remains unclear.

Long non-coding RNAs (IncRNAs) have drawn much attention because of their diagnostic, prognostic,
and predictive potential. lncRNAs, a new class and major member of the ncRNA family, are composed of at least 200 nucleotides and have limited or no protein-coding potential [9–11]. However, lncRNAs play crucial roles in the regulation of multiple biological processes related to cancer progression, tumor growth and drug resistance [12–14]. Furthermore, evidence suggests that aberrant lncRNA expression can function as a tumor suppressor [15] or oncogene [16]. For example, lncRNA H19 promotes glioma progression by targeting miR-675 [17]. In addition, the decreased expression of miR-125a-5p after lncRNA HOTAIR knockdown increases cell apoptosis by activating caspase-2 [18].

Taurine-up-regulated gene 1 (TUG1), a 7.1-kb lncRNA, was originally identified as a transcript up-regulated by taurine treatment in developing newborn mouse retinal cells. Inhibition of TUG1 expression can prevent proliferation of retinal cells, which suggests a moderating effect of TUG1 on cell growth and its participation in human tumor progression [19]. Several recent studies have confirmed TUG1 overexpression in various types of human tumors and an involvement in carcinogenesis and cancer progression. It has been reported that TUG1 is up-regulated in esophageal squamous cell carcinoma, colorectal cancer, hepatocellular carcinoma, gastric cancer, bladder cancer and hepatoblastoma and therefore promotes tumor progression [20–25]. On the other hand, TUG1 seems to be silenced in glioma and non-small cell lung cancer (NSCLC) [26–29], and thus, TUG1 may suppress the growth of some types of tumors.

Although TUG1 has been shown to have imperative functions in an increasing number of carcinomas, little is known about the expression pattern and exact role of TUG1 in human CCA. In our present study, we aimed to explore the relative expression levels of TUG1 in CCA tissues and corresponding adjacent normal tissues, and assessed the association of TUG1 with clinicopathologic features. In addition, we analyzed CCA cell growth, apoptosis, migration, invasion and epithelial-mesenchymal transition (EMT) after knockdown of TUG1 in vitro. This is the first study to reveal the functional role of TUG1 in CCA.

RESULTS

TUG1 is upregulated in CCA tissues and cell lines

To explore the expression levels of TUG1 in CCA, qRT-PCR experiments were performed on 51 pairs of CCA tissues as well as diverse CCA cell lines including KMBC, HCCC-9810, HuCCT1, CCLP-1, Huh-28, QBC939 and RBE. Additionally, we examined HIBEC cells as a control. qRT-PCR revealed that TUG1 mRNA levels were up-regulated in CCA tissues samples compared to paired non-tumor tissue with an average fold change of 3.00 (p=0.003; Figure 1A). In addition, the majority of cell lines showed substantially higher levels of TUG1 expression compared to HIBEC cells, indicating that TUG1 might be involved in tumorigenesis and progression of CCA (Huh28, p=0.038; KMBC, p=0.033; HuCCT1, p=0.003; QBC939, p<0.001; RBE, p<0.001; Figure 1B).

TUG1 overexpression is correlated with poor prognosis in CCA patients

To evaluate whether TUG1 may act as a potential diagnostic biomarker for CCA patients, the association between TUG1 and clinicopathological parameters were evaluated (Table 1). Notably, tumor size (p=0.005), TNM stage (p=0.013) and postoperative recurrence (p=0.036) correlated significantly with up-regulated TUG1 expression. However, patients’ gender, age, lymph node invasion and other parameters were not associated with TUG1. Furthermore, Kaplan–Meier survival analysis and the log-rank test applied based on postoperative survival time and TUG1 expression clearly showed that TUG1 expression was associated with a reduced overall survival time of patients after surgery (p=0.010; Figure 1C).

Figure 1: TUG1 is upregulated in both CCA tissues and cell lines, and overexpressed TUG1 decreased overall survival in patients with CCA. (A) TUG1 expression levels in CCA tissue samples and adjacent normal tissues; (B) TUG1 expression levels in CCA cell lines and HIBEC; (C) Kaplan–Meier survival analysis applied based on postoperative survival time and TUG1 expression. *p<0.05, **p<0.01, ***p<0.001.
| Clinicopathological features | No. of patients (n) | TUG1 expression | p-value |
|-----------------------------|---------------------|-----------------|---------|
|                            |                     | High (n)        | Low (n) |
| Gender                      |                     |                 |         |
| Male                        | 25                  | 14              | 11      | 0.573   |
| Female                      | 26                  | 17              | 9       |         |
| Age                         |                     |                 |         |
| <60                         | 27                  | 17              | 10      | 0.780   |
| ≥60                         | 24                  | 14              | 10      |         |
| Tumor site                  |                     |                 |         |
| Intrahepatic                | 11                  | 5               | 6       | 0.406   |
| Perihilar                   | 20                  | 12              | 8       |         |
| Distal                      | 20                  | 14              | 6       |         |
| Tumor size                  |                     |                 |         |
| <3                          | 28                  | 12              | 16      | 0.005   |
| ≥3                          | 23                  | 19              | 4       |         |
| Lymph node invasion         |                     |                 |         |
| Present                     | 28                  | 18              | 10      | 0.774   |
| Absent                      | 23                  | 13              | 10      |         |
| Vascular invasion           |                     |                 |         |
| Positive                    | 14                  | 14              | 3       | 0.198   |
| Negative                    | 37                  | 20              | 17      |         |
| TNM stage                   |                     |                 |         |
| I-II                        | 16                  | 1               | 10      | 0.013   |
| III-IV                      | 36                  | 26              | 10      |         |
| Differentiation grade       |                     |                 |         |
| Well/moderately             | 16                  | 7               | 9       | 0.126   |
| Poorly/undifferentiated     | 35                  | 24              | 11      |         |
| Postoperative recurrence    |                     |                 |         |
| Present                     | 41                  | 28              | 13      | 0.036   |
| Absent                      | 10                  | 3               | 7       |         |
| Serum CEA level             |                     |                 |         |
| >5 ng/ml                    | 30                  | 17              | 13      | 0.566   |
| ≤5 ng/ml                    | 21                  | 14              | 7       |         |
| Serum CA19-9 level          |                     |                 |         |
| >37 U/ml                    | 34                  | 19              | 15      | 0.373   |
| ≤37 U/ml                    | 17                  | 12              | 5       |         |
| HBV infection               |                     |                 |         |
| Positive                    | 22                  | 12              | 10      | 0.564   |
| Negative                    | 29                  | 19              | 10      |         |
TUG1 depletion retarded cell proliferation

To shed light on the *in vitro* functional roles of TUG1 in CCA, four specific RNA interference constructs against TUG1 and a negative control (si-NC) were designed for transfection into QBC939 and RBE cell lines as they express the highest levels of TUG1. We tested transfection efficiency by inverted fluorescence microscopy and calculated the percentage of cells expressing green fluorescent protein (Figure 2A). Additionally, flow cytometry results indicated that the transfection efficiency of the lipofectamine 3000 and si-TUG1/si-NC mixture reached 70%–90% in the two selected cell lines (Figure 2B). Moreover, qRT-PCR analysis revealed that the levels of TUG1 expression in selected cell lines were markedly silenced as shown in Figure 2C. Si-TUG1-2 and -3 were the most effective siRNAs targeting TUG1 compared to scrambled siRNA, and therefore were used in subsequent experiments. CCK-8 and Ki67 assays showed that QBC939 and RBE cell growth was restrained in TUG1

---

**Figure 2:** Transfection and knockdown efficiency of TUG1-specific siRNA and TUG1 depletion retarded cell proliferation and colony formation in CCA cells. (A) CCA cells (QBC939 and RBE) under light microscope and fluorescence microscope after transfection (×100). (B) Transfection efficiency of CCA cells (QBC939 and RBE) was detected by flow cytometry. (C) CCA cells (QBC939 and RBE) were transfected with si-RNA specifically targeting TUG1 or si-NC, and siRNA-depletion efficiency was examined by real-time PCR. (D) The proliferation of CCA cells (QBC939 and RBE) after transfection was measured by CCK-8 proliferation assay. (E) The proliferation of CCA cells (QBC939 and RBE) after transfection was measured by Ki67 immunofluorescence assay. (F) The colony formation capacity of CCA cells (QBC939 and RBE) after transfection was measured by clonogenic assay. (G) The protein level of PCNA in CCA cells (QBC939 and RBE) after transfection was measured by Western blot assay. *p<0.05, **p<0.01, ***p<0.001.
depleted groups (Figure 2D and 2E). Consist with these data, after transfection with si-TUG1-2 or si-TUG1-3, clonogenic ability was remarkably weakened as shown by the colony formation assay (Figure 2F). Moreover, PCNA was down-regulated after knockdown of TUG1 proved by Western blot assay (Figure 2G).

The role of si-TUG1 in promoting CCA cell apoptosis

In order to investigate the potential impact of TUG1 on apoptosis of CCA cells, flow cytometry analysis, AO/EB double fluorescence staining and TUNEL assay were conducted. A multitude of cells transfected with si-NC were alive and did not stain positive for Annexin-V and PI in both QBC939 and RBE cells, whereas in the si-TUG1 counterpart groups, early and late apoptotic cells increased dramatically (Figure 3A). Subsequent AO/EB and TUNEL staining assays showed similar results (Figure 3B and 3C). It has been reported that down-regulation of TUG1 induced cell apoptosis by stimulating the expression of caspase-3 and caspase-9 in human breast cancer [30]. Similarly, relative activities of caspase-3 and -9 were significantly increased in si-TUG1 treatment groups compared to si-NC group (Figure 4A). The Western blot results demonstrated that silenced TUG1 activated Bax protein expression and restrained the protein level of Bcl-2 compared to negative control group (Figure 4B).

**Figure 3: Silencing of TUG1 induced apoptosis in CCA cells.** (A) The apoptosis of CCA cells (QBC939 and RBE) after transfection was evaluated by flow cytometry. (B) The apoptosis of CCA cells (QBC939 and RBE) after transfection was evaluated by AO/EB double fluorescence staining assay (×200). (C) The apoptosis of CCA cells (QBC939 and RBE) after transfection was evaluated by TUNEL staining assay. *p<0.05, **p<0.01.
Knockdown of TUG1 inhibited CCA cell metastasis in vitro

To evaluate the extent of TUG1 function in other aspects of CCA, such as migration and invasion, a wound healing assay and Transwell assay were conducted in QBC939 and RBE cells transfected with si-NC or selected siRNAs specifically targeting TUG1. Interestingly, TUG1 depletion leads to prolonged healing times compared with si-NC groups (Figure 5A). Furthermore, the migratory ability as well as invasion potential of selected cells obviously decreased due to TUG1 depletion (Figure 5B and 5C). The above results demonstrated that the down-regulation of TUG1 greatly suppressed RBE and QBC939 cell metastasis in vitro.

Silenced TUG1 reversed EMT in CCA cells

EMT is closely correlated with cell invasion capacity. Therefore, to assess the relationship between dysregulation of TUG1 and EMT, EMT markers including E-cadherin, N-cadherin and Vimentin were analyzed by Western blot. The results shown in Figure 6A and 6B demonstrated that the protein expression level of E-cadherin was significantly increased, while N-cadherin and Vimentin were lost in QBC939 and RBE cells when TUG1 was silenced. These data implied that the down-regulation of TUG1 reversed EMT in CCA cells.

DISCUSSION

CCA remains one of the most lethal malignancies among people despite great efforts to reverse this situation. For this reason, it is urgent to identify novel biomarkers to improve the early diagnostic rate and to explore therapeutic targets for CCA patients. LncRNAs were mistaken for useless byproducts of transcription for a long time. However, during the past decade, they were proven to be imperative elements in cell biology and human diseases, especially for various carcinomas. For example, HOTAIR, POU3F3, 91H, ZFAS1 and many other lncRNAs were shown to have multiple fundamental roles in several types of carcinomas [31–34]. To date, several CCA-associated lncRNAs have been recognized. For instance, IncRNA H19 and HULC promote cell migration and invasion using a ceRNA method under oxidative stress [35].

Recently, increasing evidence has indicated that the newly identified lncRNA molecule TUG1 plays crucial roles in tumorigenesis and in the progression of certain types of carcinomas [36] and these data have provided new insights into CCA. Aberrant upregulated TUG1 has been detected in various types of carcinomas, such as osteosarcoma, ovarian cancer, colon cancer, bladder carcinoma, esophageal squamous cell cancer and kidney cancer [37–42]. In bladder cancer, TUG1 suppressed the expression of miR-145 and there was a mutual suppression...
Figure 5: Knockdown of TUG1 inhibited cell migration and invasion potential in CCA cells. (A) The migration of CCA cells (QBC939 and RBE) after transfection was examined by wound healing assay (×50). (B) The migration of CCA cells (QBC939 and RBE) after transfection was examined by Transwell migration assay (×200). (C) The invasion of CCA cells (QBC939 and RBE) after transfection was examined by Transwell invasion assay (×200). *p<0.05, **p<0.01.
between TUG1 and miR-145. Besides, ZEB2 functioned as a downstream target of miR-145. Thus, TUG1 exerted an oncogene via miR-145/ZEB2 axis [40]. Huang et al. demonstrated that TUG1 was activated by the nuclear transcription factor SP1 in HCC, and upregulation of TUG1 could inhibit the tumor-suppressor gene Kruppel-like factor 2 (KLF2) via binding to polycomb repressive complex 2 (PRC2) and recruiting it to KLF2 promoter region [22]. Interestingly, TUG1 expression in glioma, along with NSCLC was found to be down-regulated and acted as a tumor suppressor [26–29]. Tissue-specific expression is ubiquitous and might explain this phenomenon [43]. In agreement with all of the digestive system neoplasms studied to date, the results of our investigation verified that TUG1 was higher in CCA tissue samples and CCA cell lines compared with corresponding healthy tissue samples and HIBEC cells, respectively. Additionally, high expression of TUG1 was closely associated with tumor size, TNM stage, postoperative relapse and overall survival of CCA patients. Therefore, IncRNA TUG1 may serve as a potential prognostic indicator for CCA.

Proliferation is one of the most basic characteristics of cancer. Herein, CCK-8 proliferation assay, Ki67 immunofluorescent staining and colony formation assay were performed to evaluate the proliferative activity of CCA. PCNA is widely known as an imperative factor in the metabolism of nucleic acid and mainly functioned in DNA replication, DNA repair, chromatin assembly and RNA transcription [44]. In our study, CCA cell proliferation was remarkably inhibited along with the loss of PCNA and Ki67 followed by silencing of TUG1, indicating that TUG1 promotes tumor development and progression in CCA.

Apoptosis is an effective pathway to eliminate unnecessary cells. Among these, caspase-3 (effector caspase) and caspase-9 (initiator caspase) play key roles in the process of cell apoptosis. Bcl-2 family proteins function as central regulators of cell life and death. Apoptosis signaling can be activated by receptor-mediated pathway and mitochondria pathway [45]. Both of the pathways are associated with the activation of caspase-3, caspase-9, Bax and Bcl-2 [46]. In the present study, down-regulated TUG1 induced cell apoptosis by activating the expression of caspase-3 and Bax, as well as suppressing Bcl-2 expression. The results suggested that Bcl-2/caspase-3 pathway might play key roles in mediating apoptosis induced by downregulation of TUG1.

EMT, which is characterized by lack of intercellular contacts, increasing components of the contractile cytoskeleton, drives the initiation of metastasis [47, 48]. Conversely, a reverse of EMT is essential for migrating cells to colonize a secondary site. EMT markers, such as

Figure 6: Silenced TUG1 reversed EMT in CCA cells. (A) The expression levels of EMT-related proteins in QBC939 cells after transfection were determined by Western blot assay. (B) The expression levels of EMT-related proteins in RBE cells after transfection were determined by Western blot assay. *p<0.05, **p<0.01.
E-cadherin and Claudins are down-regulated, whereas non-epithelial markers, especially N-cadherin, Vimentin and Fibronectin are over-expressed in the process of EMT. It has been reported that a switch between E-cadherin and N-cadherin is the key step of invasiveness alteration in CCA [49]. Besides, IncRNAs are emerging as potent regulators of tumor metastasis and EMT [50, 51]. Therefore, a Western blot assay was carried out and revealed that silenced TUG1 could impair migratory and invasive potential of QBC939 and RBE cells by reversing EMT progress. These findings demonstrated that cell metastasis of CCA determined by EMT-related gene expression could be regulated by TUG1 silencing.

In conclusion, our findings provide the first depiction of the biological function of IncRNA TUG1 in CCA. However, further studies are needed to unravel the precise mechanism behind the altered expression of TUG1 in CCA. Collectively, we showed that TUG1 is an important prognostic factor for CCA patients and significantly contributes to CCA progression. These results may provide a strategy and facilitate the exploration of TUG1 directed diagnostics and therapeutics against CCA.

MATERIALS AND METHODS

Patients and tissue samples

Fifty-one CCA patients who underwent radical surgical procedures at the Second Affiliated Hospital of Harbin Medical University from 2010 to 2012 were enrolled in the study. All patients gave their written informed consent approved by the Ethics Review Committees of Harbin Medical University. In addition, no patients underwent preoperative anticancer therapy. After surgery, fresh tissue specimens were collected and frozen in liquid nitrogen to avoid RNA degradation.

Cell lines and culture

HCCC-9810 and RBE were commercially obtained from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). Human intrapatic biliary epithelial cells (HIBECC), and CCA cell lines including QBC939, Huh-28, HuCCT1, KMBC and CCLP-1 were preserved in our laboratory. Cells were cultured in dulbecco’s modified eagle medium (DMEM) or RPMI-1640 containing 10% fetal bovine serum (FBS) (Invitrogen Life Technologies, USA) in a 37°C humidified atmosphere at 5% CO2. All cell lines were passaged for no more than six months.

RNA extraction and qRT-PCR

Total RNA from samples or cells were extracted by TRIzol reagent (Invitrogen, Waltham, USA) following the manufacturer’s recommendations and converted to cDNA using Transcriptor First Strand cDNA Synthesis Kit (Roche, Germany). qRT-PCR was performed with FastStart Universal SYBR Green Master (Roche, Germany) in a BIO-RAID C1000 Thermal Cycler. GAPDH served as an endogenous control. The following primer sets for TUG1 or GAPDH were used for real-time PCR: TUG1 Forward, 5'-TAGCAGTCCCCCAATCTCTTG-3' Reverse, 5'-CACAAATCCCATCATTCCC-3'; GAPDH Forward, 5'-GGGAGCCAAAAGGGCTCAT-3' Reverse, 5'-GAGTCCTTCACGATACCAA-3'. Gene expression was calculated by delta-delta CT method.

siRNAs and transfection

Cells were transfected with either a small interfering RNA targeting TUG1 or the nonspecific scrambled siRNA (GenePharma, Shanghai, China) using Lipofectamine 3000 (Invitrogen) and serum-free medium. Following transfection (6 h), cells were transferred to complete medium with 10% FBS and antibiotics. Fluorescently labeled siRNAs were counted using an inverted fluorescence microscope, flow cytometry was used to examine transfection efficiency, and TUG1 depletion efficiencies were analyzed by real time PCR. The target sequences of si-TUG1 are shown below: si-TUG1-1, sense 5'-CCUCAGAUCUCAUCAAAUTT-3' antisense 5'-UUUAAGAGAUGAGUGGTT-3'; si-TUG1-2, sense 5'-GCAGAGCUCUGUAUAAUTT-3' antisense 5'-AAAAUAACAGAUGACUCGGTC-3'; si-TUG1-3, sense 5'-GCUGUGCUUUCAUUCUGACCCCUU -3' antisense 5'-AAAGGAUUGAGCGAGAA AGAAGCCAAGC -3'; si-TUG1-4, sense 5'-GGUAUAGGCAAGAACATT -3' antisense 5'-UUGUUCUCUGGCUUAUCCCTT-3'.

Proliferation assays

For CCK-8 analysis, QBC939 and RBE cells transfected with TUG1 siRNA or si-NC were transferred into 96-well plates at a concentration of 1500 cells per well. Cell Counting Kit-8 (Dojindo, Tokyo, Japan) was used to assess cell viability. Reagents were added into corresponding wells at each monitored time (0, 24, 48, 72, and 96 h) and the plate was then incubated at 37°C for 1.5 h before absorbance at 450 nm was measured using a microplate reader (Tecan). For the Ki67 immunofluorescence assay, treated cells were planted into 24-well plates on cover glass. Briefly, after fixation with Immunostaining Permeabilization Buffer with Triton X-100 (Beyotime, Beijing, China) and blocked with 5% bovine serum albumin, cells were incubated with anti-Ki67 monoclonal antibody (Abcam, USA) overnight at 4°C. Next, cells were probed with secondary antibody and 4, 6-Diamidino-2-phenylindole (DAPI) (Beyotime, Beijing, China) was applied to color the nuclei. An inverted fluorescent microscope (Leica, Germany) was used to observe and take photographs.
For the clonogenic assay, QBC939 and RBE cells were trypsinized into a single-cell suspension and plated in a 3.5-cm dish at a total of 500 cells per well. The cells were maintained in an incubator for approximately 2 weeks until there were visible colonies formation. After fixation with paraformaldehyde and staining with crystal violet (Beyotime, Beijing, China), colonies were counted from three randomly chosen fields.

**Flow cytometry for cell apoptosis**

To detect apoptosis, transfected cells were collected and washed twice with cold PBS. The cells were measured by flow cytometry (FACScan; BD Biosciences, USA) after double staining with 5 μl FITC-Annexin V and 5 μl Propidium iodide (PI) using FITC Annexin V Apoptosis Detection Kit (BD, Biosciences, USA) in accordance with the manufacturer’s recommendations. The percentage of apoptotic cells was determined and then compared in each group.

**Acridine orange/ethidium bromide (AO/EB) double fluorescence staining**

Cells transfected with si-TUG1 or si-NC in the exponential growth phase were cultured in an incubator of 5% CO₂ at 37°C, followed by staining with prepared AO/EB mixing solution for 5 min (Solarbio, Beijing, China). AO/EB staining could distinguish live cells from apoptotic cells by their different abilities to penetrate the cell membrane. AO could permeate intact cell membrane and color the nuclei in green fluorescence. Conversely, EB stains DNA with orange fluorescence only when the cell membrane is broken. A fluorescence microscope (Leica, Germany) was used to count and take photographs.

**TdT-mediated dUTP Nick-End Labeling (TUNEL) assay**

One Step TUNEL Apoptosis Assay Kit (Beyotime, Beijing, China) was used to detect cell apoptosis. Treated cells were fixed with paraformaldehyde for 30 min. After washing with PBS, cells were incubated with Immunostaining Permeabilization Buffer with Triton X-100 (Beyotime, Beijing, China). Afterwards, cells were treated with 45 μl fluorescent labeled reagent and 5 μl terminal deoxynucleotidyl transferase (TdT) before incubated at 37°C for 60 min. Cells were observed by a fluorescence microscope (Leica, Germany).

**Caspases analysis**

Total cell proteins were extracted after 48 h siRNA treatment, and 10 μl protein from each group was incubated with 90 μl of provided reaction buffer and Ac-DEVD-pNA (2 mM) in 96-well plates at 37°C for 4 h following the manufacturer’s instructions (Solarbio, Beijing, China). Afterwards, reaction mixtures were detected using a microplate reader at a wavelength of 405 nm and relative activities of caspase-3 and -9 were compared between the si-TUG1 groups and the corresponding si-NC group.

**Scratch wound assay**

Transfected cells were seeded as a monolayer in 3.5-cm dishes and cultured to a density of 80%. Then, straight wounds were softly scratched by a sterile 200-μL pipette tip and rinsed three times with phosphate buffer solution (PBS) to clean up cellular debris. Photographs were taken 0 h and 36 h after wound formation.

**Migration and invasion assay**

To analyze the degree of migration, QBC939 and RBE cells (5 × 10⁴ cells/well) were detached with serum-free RPMI-1640 and loaded in the upper section of a 24-well transwell unit with 8-μm polycarbonate nucleopore filters (Corning, NY, USA). The lower chamber was filled with 600 μl medium containing 10% FBS. The transwell unit was incubated for 24 h before the cells on the lower surface of the membrane were fixed and stained with crystal violet. Cells from at least five representative fields were analyzed.

**Western blot analysis**

Forty-eight hours post-transfection, QBC939 or RBE cells were digested with trypsin (Beyotime, Beijing, China) and lysed with RIPA lysis buffer (Beyotime, Beijing, China) supplemented with protease inhibitors. Equal amounts of extracted proteins were fractionated by sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) vertical electrophoresis, followed by transfer onto a 0.45 μm polyvinylidene fluoride (PVDF) membrane (GE Healthcare, Piscataway, NJ, USA). The membrane was blocked with 5% skim milk diluted in Tris-buffered saline containing 0.05% Tween-20 for 1.5 h at room temperature and then probed with primary antibodies to E-cadherin, N-cadherin, Vimentin, PCNA, Bax or Bel-2 (Abcam, USA) overnight. After washing and incubating with secondary antibody (Cell Signaling Technology, Danvers, USA) for 2 h, BeyoECL Plus Kit (Beyotime, Beijing, China) was used to visualize the blots.

**Statistical analysis**

Data were obtained from at least three independent experiments, presented as the mean ± standard deviation (SD), and analyzed using Student’s t test. Fisher’s exact
test was used in clinicopathological associations of TUG1 expression. A p<0.05 value was considered significant.

**Abbreviations**

AO/EB: acridine orange/ethidium bromide; CA19-9: carbohydrate antigen 19-9; CCA: cholangiocarcinoma; CEA: carcino embryonie antigen; DAPI: 4, 6-diamidino-2-phenylindole; DMEM: dulbecco's modified eagle medium; ECC: extrahepatic cholangiocarcinoma; EMT: epithelial-mesenchymal transition; FBS: fetal bovine serum; HCC: hepatocellular carcinoma; HBV: hepatitis B virus; HIBEC: human intrahepatic biliary epithelial cell; ICC: intrahepatic cholangiocarcinoma; KLF2: Kruppel-like factor 2; lncRNA: long non-coding RNA; NSCLC: non-small cell lung cancer; PBS: phosphate buffer solution; PCNA: proliferating cell nuclear antigen; PI: propidium iodide; PVDF: polyvinylidene fluoride; SD: standard deviation; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel; TdT: terminal deoxynucleotidyl transferase; TUG1: taurine-upregulated gene 1; TUNEL: TdT-mediated dUTP Nick-End Labeling.

**Author contributions**

Conceived and designed the experiments: Yunfu Cui, Xingming Jiang.

Performed the experiments: Yi Xu, Kaiming Leng, Zhenglong Li.

Wrote the manuscript: Yi Xu, Xiangyu Zhong.

Analyzed the data: Yi Xu, Xingming Jiang, Pengcheng Kang, Fumin Zhang.

Revised the manuscript: Yunfu Cui.

All authors read and approved the final manuscript.

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest.

**FUNDING**

This study was funded by National Natural Science Foundation of China (Grant No.81602088 and 81170426), Health and Family Planning Commission Research Project of Heilongjiang Province (Grant No.2016-049), Heilongjiang Postdoctoral Science Foundation (Grant No.LBH-Z16096), Postgraduate innovative research project of Harbin Medical University (Grant No.YJSCX2016-21HYD), Innovative Science Foundation of Harbin Medical University (Grant No.2016LCZX09) and National Science Foundation of Heilongjiang Province (Grant No. H201396).

**REFERENCES**

1. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015; 29:221–232.

2. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012; 61:1657–1669.

3. Tyson GL, Ilyas JA, Duan Z, Green HK, Younes M, El-Serag HB, Davila JA. Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification. Dig Dis Sci. 2014; 59:3103–3110.

4. Alberts SR, Gores GJ, Kim GP, Roberts LR, Kendrick ML, Rosen CB, Chari ST, Martenson JA. Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin Proc. 2007; 82:628–637.

5. DeOliveira ML, Cunningham AB, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD. Cholangiocarcinoma: thirty-one year experience with 564 patients at a single institution. Ann Surg. 2007; 245:755–762.

6. Lau SH, Lau WY. Current therapy of hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2012; 11:12–17.

7. Skipworth JR, Olde Damink SW, Imber C, Bridgewater J, Pereira SP, Malago M. Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer. Aliment Pharmacol Ther. 2011; 34:1063–1078.

8. Kongpetch S, Jusakul A, Ong CK, Lim WK, Rozen SG, Teh BT. Pathogenesis of cholangiocarcinoma: from genetics to signaling pathways. Best Pract Res Clin Gastroenterol. 2015; 29:233–244.

9. Derrien T, Johnson R, Bussotti G, Carey BW, Dunker AK, Dunham I, Hardison CW, Hubbard T, Lanthier S, Lee L, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012; 22:1775–1789.

10. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489:57–74.

11. Guttmann M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, Young G, Lucas AB, Ach R, Bruhn L, Yang X, Amit I, Meissner A, et al. LincRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011; 477:295–300.

12. Zhang EB, Kong R, Yin DD, You LH, Sun M, Han L, Xu TP, Xia R, Yang JS, De W, Chen JF. Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget. 2014; 5:2276–2292. doi: 10.18632/oncotarget.1902.

13. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016; 29:452–463.

14. Malek E, Jagnannathan S, Driscoll JJ. Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget. 2014; 5:8027–8038. doi: 10.18632/oncotarget.2469.
15. Yin DD, Liu ZJ, Zhang E, Kong R, Zhang ZH, Guo RH. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Tumour Biol. 2015; 36:4851–4859.

16. Liu L, Liu Y, Zhuang C, Xu W, Fu X, Lv Z, Wu H, Mou L, Zhao G, Cai Z, Huang W. Inducing cell growth arrest and apoptosis by silencing long non-coding RNA PCAT-1 in human bladder cancer. Tumour Biol. 2015; 36:7685–7689.

17. Shi Y, Wang Y, Luan W, Wang P, Tao T, Zhang J, Qian J, Liu N, You Y. Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675. PLoS One. 2014; 9:e86295.

18. Tang L, Shen H, Li X, Li Z, Liu Z, Xu J, Ma S, Zhao X, Bai X, Li M, Wang Q, Ji J. MiR-125a-5p decreases after long non-coding RNA HOTAIR knockdown to promote cancer cell apoptosis by releasing caspase 2. Cell Death Dis. 2016; 7:e2137.

19. Young TL, Matsuda T, Cepko CL. The noncoding RNA taurine upregulated gene 1 is required for differentiation of the murine retina. Curr Biol. 2005; 15:501–512.

20. Jiang L, Wang W, Li G, Sun C, Ren Z, Sheng H, Gao H, Wang C, Yu H. High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma. Cancer Chemother Pharmacol. 2016; 78:333–339.

21. Wang L, Zhao Z, Feng W, Ye Z, Dai W, Zhang C, Peng J, Wu K. Long non-coding RNA TUG1 promotes colorectal cancer metastasis via EMT pathway. Oncotarget. 2016; 7:51713–51719. doi: 10.18632/oncotarget.10563.

22. Huang MD, Chen WM, Qi FZ, Sun M, Xu XR, Ma P, Shu YQ. Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2. Mol Cancer. 2015; 14:165.

23. Zhang E, He X, Yin D, Han L, Qin M, Xu T, Xu R, Xu L, Yin R, De W. Increased expression of long noncoding RNA TUG1 predicts poor prognosis of ovarian cancer and regulates cell proliferation by epigenetically silencing of p57. Cell Death Dis. 2016; 7:e2109.

24. Iliev R, Kleinova R, Juracek J, Dolezel J, Ozanova Z, Fedorov M, Pacik D, Svoboda M, Stanik M, Slaby O. Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer. Tumour Biol. 2016; 37:13385–13390.

25. Dong R, Liu QB, Liu BH, Chen G, Li K, Zheng S, Dong KR. Targeting long non-coding RNA-TUG1 inhibits tumor growth and angiogenesis in hepatoblastoma. Cell Death Dis. 2016; 7:e2278.

26. Li J, Zhang M, An G, Ma Q. LncRNA TUG1 acts as a tumor suppressor in human glioma by promoting cell apoptosis. Exp Biol Med (Maywood). 2016; 241:644–649.

27. Li J, An G, Zhang M, Ma Q. Long non-coding RNA TUG1 acts as a miR-26a sponge in human glioma cells. Biochem Biophys Res Commun. 2016; 477:743–748.

28. Lin PC, Huang HD, Chang CC, Chang YS, Yen JC, Lee CC, Chang WH, Liu TC, Chang JG. Long noncoding RNA TUG1 is downregulated in non-small cell lung cancer and can regulate CELF1 on binding to PRC2. BMC Cancer. 2016; 16:583.

29. Zhang EB, Yin DD, Sun M, Kong R, Liu XH, You LH, Han L, Xia R, Wang KM, Yang JS, De W, Shu YQ, Wang ZX. P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. Cell Death Dis. 2014; 5:e1243.

30. Li T, Liu Y, Xiao H, Xu G. Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer. Breast Cancer. 2017; 24:535–543. https://doi.org/10.1007/s12282-016-0736-x.

31. Lee NK, Lee JH, Kim WK, Yun SY, Youn YH, Park CH, Choi YY, Kwon TH, Lee SK. Promoter methylation of PCDH10 by HOTAIR regulates the progression of gastrointestinal stromal tumors. Oncotarget. 2016; 7:75307–75318. doi: 10.18632/oncotarget.12171.

32. Shan T, Xu JH, Yu T, Li JY, Zhao LN, Ouyang H, Luo S, Lu XJ, Huang CZ, Lan QS, Zhong W, Chen QK. Knockdown of line-POU3F3 suppresses the proliferation, apoptosis, and migration resistance of colorectal cancer. Oncotarget. 2016; 7:961–975. doi: 10.18632/oncotarget.5830.

33. Vennin C, Spruyt N, Robin YM, Chassat T, Le Bourhis X, Adriaenssens E. The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications. Cancer Lett. 2017; 385:198–206.

34. Thorenoor N, Faltejskova-Vychytilova P, Hombach S, Milcochova J, Kretz M, Svoboda M, Slaby O. Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer. Oncotarget. 2016; 7:622–637. doi: 10.18632/oncotarget.5807.

35. Wang WT, Ye H, Wei PP, Han BW, He B, Chen ZH, Chen YQ. LncRNAs H19 and HULC, activated by oxidative stress, promote cell migration and invasion in cholangiocarcinoma through a ceRNA manner. J Hematol Oncol. 2016; 9:117.

36. Li J, An G, Zhang M, Ma Q. Long non-coding RNA TUG1 acts as a tumor suppressor in human glioma by promoting cell apoptosis. Exp Biol Med (Maywood). 2016; 241:644–649.
38. Kuang D, Zhang X, Hua S, Dong W, Li Z. Long non-coding RNA TUG1 regulates ovarian cancer proliferation and metastasis via affecting epithelial-mesenchymal transition. Exp Mol Pathol. 2016; 101:267–273.
39. Sun J, Ding C, Yang Z, Liu T, Zhang X, Zhao C, Wang J. The long non-coding RNA TUG1 indicates a poor prognosis for colorectal cancer and promotes metastasis by affecting epithelial- mesenchymal transition. J Transl Med. 2016; 14:42.
40. Tan J, Qiu K, Li M, Liang Y. Double-negative feedback loop between long non-coding RNA TUG1 and miR-145 promotes epithelial to mesenchymal transition and radioresistance in human bladder cancer cells. FEBS Lett. 2015; 589:3175–3181.
41. Xu Y, Wang J, Qiu M, Xu L, Li M, Jiang F, Yin R, Xu L. Upregulation of the long noncoding RNA TUG1 promotes proliferation and migration of esophageal squamous cell carcinoma. Tumour Biol. 2015; 36:1643–1651.
42. Zhang M, Lu W, Huang Y, Shi J, Wu X, Zhang X, Jiang R, Cai Z, Wu S. Downregulation of the long noncoding RNA TUG1 inhibits the proliferation, migration, invasion and promotes apoptosis of renal cell carcinoma. J Mol Histol. 2016; 47:421–428.
43. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, Rinn JL. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011; 25:1915–1927.
44. Jurikova M, Danihel L, Polak S, Varga I, Ki67, PCNA, and MCM proteins: markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 2016; 118:541–552.
45. Evan G, Littlewood T. A matter of life and cell death. Science. 1998; 281:1317–1322.
46. Montero JA, Hurle JM. Sculpturing digit shape by cell death. Apoptosis. 2010; 15:365–375.
47. Ye X, Weinberg RA. Epithelial–mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol. 2015; 25:675–686.
48. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15:178–196.
49. Araki K, Shimura T, Suzuki H, Terao K, Wada W, Yajima T, Kobayashi T, Kubo N, Tsubakimoto H. E-cadherin switch mediates cancer progression via TGF-eta-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer. 2011; 105:1885–1893.
50. Kim HJ, Eoh KJ, Kim LJ, Shin EJ, Kim SO, Kim KH, Lee JK, Kim SW, Kim AJ. The long noncoding RNA HOXA11 antisense induces tumor progression and stemness maintenance in cervical cancer. Oncotarget. 2016; 7:83001–83016. doi: 10.18632/oncotarget.12863.
51. Miao LY, Huang Z, Zengli Z, Li H, Chen QF, Yao CY, Cai HR, Xiao YL, Xiu HP, Wang YS. Loss of long noncoding RNA FOXF1-AS1 regulates epithelial-mesenchymal transition, stemness and metastasis of non-small cell lung cancer cells. Oncotarget. 2016; 7:68339–68349. doi: 10.18632/oncotarget.11630.